SCHEMBL18957095

SCHEMBL18957095

CC(C)C(=O)OCOC(=O)c1cccc2c1OB(O)C(NC(=O)CCCC(F)(F)F)C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18957093 1.00 — —
SCHEMBL18957034 0.96 NAMPT (0.32) —
SCHEMBL18957033 0.96 NAMPT (0.32) —
SCHEMBL18966506 0.93 — —
SCHEMBL18957230 0.92 — —
SCHEMBL18957229 0.92 — —
SCHEMBL18957109 0.92 — —
SCHEMBL18966653 0.92 PRKCB (0.32) —
SCHEMBL18957111 0.92 — —
SCHEMBL18966615 0.91 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10464952-B2 Beta-lactamase inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2019-11-05 — — US disclosed
US-20180291039-A1 BETA-LACTAMASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-10-11 — — US disclosed
WO-2017100537-A1 BETA-LACTAMASE INHIBITORS VenatoRx Pharmaceuticals, Inc. (US) 2017-06-15 — — WO disclosed
Send feedback